Q3 EPS Estimates for Avanos Medical Cut by Zacks Research

Avanos Medical, Inc. (NYSE:AVNS) – Equities researchers at Zacks Research cut their Q3 2025 earnings estimates for Avanos Medical in a report released on Wednesday, November 20th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.41 for the quarter, down from their previous forecast of $0.57. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical’s Q4 2025 earnings at $0.53 EPS and FY2025 earnings at $1.64 EPS.

Separately, StockNews.com lowered Avanos Medical from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 3rd.

Avanos Medical Stock Performance

Shares of AVNS opened at $18.60 on Monday. The company has a current ratio of 2.22, a quick ratio of 1.46 and a debt-to-equity ratio of 0.12. The stock has a fifty day moving average price of $21.73 and a 200-day moving average price of $21.54. The firm has a market cap of $854.86 million, a PE ratio of 54.71 and a beta of 0.92. Avanos Medical has a 12 month low of $17.39 and a 12 month high of $25.36.

Institutional Investors Weigh In On Avanos Medical

Several hedge funds have recently added to or reduced their stakes in the business. State Board of Administration of Florida Retirement System lifted its holdings in shares of Avanos Medical by 8.6% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 19,053 shares of the company’s stock valued at $379,000 after buying an additional 1,516 shares during the period. Tidal Investments LLC acquired a new stake in shares of Avanos Medical during the 1st quarter worth approximately $439,000. Boston Partners purchased a new position in shares of Avanos Medical during the 1st quarter valued at approximately $571,000. Azzad Asset Management Inc. ADV lifted its stake in shares of Avanos Medical by 8.5% in the 2nd quarter. Azzad Asset Management Inc. ADV now owns 28,521 shares of the company’s stock valued at $568,000 after purchasing an additional 2,223 shares during the period. Finally, Natixis Advisors LLC lifted its stake in shares of Avanos Medical by 19.5% in the 2nd quarter. Natixis Advisors LLC now owns 18,878 shares of the company’s stock valued at $376,000 after purchasing an additional 3,077 shares during the period. 95.17% of the stock is owned by hedge funds and other institutional investors.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.